Quillivant XR | PharmaShots

Tris Pharma Acquires Pfizer’s NextWave Pharmaceuticals for its Two ADHD

Shiwani Sharma September 26, 2018

Shots: The acquisition includes NextWave with its two novels ADHD (Attention Deficit Hyperactivity Disorder) treatments, co-developed by NextWave and Tris using Tris’ novel, LiquiXR platform Tris has expanded its ADHD […]Read More

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting Genetic Modifiers

Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Merck’s Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies

Alexion’s Ultomiris (ravulizumab) Receives the CHMP’s Positive Opinion for its New Advanced Formulation

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

Novartis’ Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Tags : Quillivant XR